Stephen F. Mahoney

CIK: 0001741389

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

$Viridian Therapeutics, Inc.\DE logo$

VRDN

Viridian Therapeutics, Inc.\DE

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
7.4K shares at avg. $30.19$224K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Exercise(M)
Direct
18.4K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
7.6K shares at avg. $29.32$224K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Restricted Stock Units
Direct
111.9K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
559.6K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Restricted Stock Units
Direct
73.4K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
440.6K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Sep 27, 2024
Purchase(P)
Direct
21.4K shares at avg. $23.33$499K

		Type	Shares	Price		Ownership
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	7,408	$30.19	$223,648	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Exercise(M)	18,357	-	$0	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	7,627	$29.32	$223,624	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	111,900	-	-	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	559,600	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	73,428	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	440,565	-	-	Direct
Sep 27, 2024	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Purchase(P)	21,400	$23.33	$499,262	Direct

1-8 of 8 transactions

About Mahoney Stephen F.

Mahoney Stephen F. (SEC CIK 0001741389) files insider reports with the SEC as President and CEO of Viridian Therapeutics, Inc.\DE (VRDN).

Signal8 holds 4 ownership filings by Mahoney Stephen F., all Form 4s, filed between Sep 30, 2024 and Mar 9, 2026. Those filings report 8 transactions, from Sep 27, 2024 to Mar 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mahoney Stephen F.'s filings is in WALTHAM, MA.

Recent filings by Mahoney Stephen F.

Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 3, 2026: Option exercise of VRDN shares (Form 4, code M).
Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 2, 2026: Grants or awards of VRDN derivative securities (2 lines, Form 4, code A).
Mar 3, 2025: Grants or awards of VRDN derivative securities (2 lines, Form 4, code A).

Other insiders filing for Viridian Therapeutics, Inc.\DE (VRDN)

Tousignant Jennifer, Chief Legal Officer
Tripuraneni Radhika, Chief Medical Officer
CAIN CHRISTOPHER W., Director
Ajer Jeffrey Robert, Director
Moses Jennifer K., Director
Gheuens Sarah, Director

How to read Form 4 transaction codes